Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Novartis Novartis Vaccines |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00316628 |
The purpose of this study is to evaluate safety and immunogenicity of a single intramuscular (IM) injection of an adjuvanted influenza vaccine in elderly subjects.
Condition | Intervention | Phase |
---|---|---|
Influenza |
Biological: influenza vaccine |
Phase II |
Study Type: | Interventional |
Study Design: | Prevention, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, (Adjuvanted With MF59C.1) Influenza Vaccine, Formulation 2005-2006, When Administered to Elderly Subjects. |
Estimated Enrollment: | 50 |
Study Start Date: | June 2005 |
Ages Eligible for Study: | 65 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Italy | |
G. D'Annunzio University | |
Chieti, Italy, 66100 | |
Office of Hygiene and Public Health, ASL Lanciano | |
Lanciano, Italy |
Study Director: | Novartis Vaccines - Drug Information Services | Novartis |
Study ID Numbers: | V70P3S, Eudract number: 2005-000621-38 |
Study First Received: | April 19, 2006 |
Last Updated: | September 13, 2006 |
ClinicalTrials.gov Identifier: | NCT00316628 |
Health Authority: | Italy: Ministry of Health |
influenza elderly vaccine |
Virus Diseases Respiratory Tract Diseases Respiratory Tract Infections Influenza, Human Orthomyxoviridae Infections |
RNA Virus Infections |